Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 530

1.

Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts.

Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB.

Cancer. 2019 Oct 22. doi: 10.1002/cncr.32557. [Epub ahead of print]

PMID:
31639200
2.

Selecting Active Surveillance: Decision-Making Factors for Men with a Low-Risk Prostate Cancer.

Hoffman RM, Lobo T, Van Den Eeden SK, Davis KM, Luta G, Leimpeter AD, Aaronson D, Penson DF, Taylor K.

Med Decis Making. 2019 Oct 21:272989X19883242. doi: 10.1177/0272989X19883242. [Epub ahead of print]

PMID:
31631745
3.

Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B.

Drug Saf. 2019 Oct 5. doi: 10.1007/s40264-019-00867-6. [Epub ahead of print]

PMID:
31587137
4.

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer.

Higano CS, Armstrong AJ, Sartor AO, Vogelzang NJ, Kantoff PW, McLeod DG, Pieczonka CM, Penson DF, Shore ND, Vacirca J, Concepcion RS, Tutrone RF, Nordquist LT, Quinn DI, Kassabian V, Scholz MC, Harmon M, Tyler RC, Chang NN, Tang H, Cooperberg MR.

Cancer. 2019 Dec 1;125(23):4172-4180. doi: 10.1002/cncr.32445. Epub 2019 Sep 4.

PMID:
31483485
5.

Editorial Comment.

Penson DF.

J Urol. 2019 Aug 20:10109701JU000058048854930cf. doi: 10.1097/01.JU.0000580488.54930.cf. [Epub ahead of print] No abstract available.

PMID:
31430239
6.

Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy.

Barzi A, Lara PN Jr, Tsao-Wei D, Yang D, Gill IS, Daneshmand S, Klein EA, Pinski JK, Penson DF, Quinn DI, Sadeghi S.

Cancer. 2019 Nov 1;125(21):3853-3863. doi: 10.1002/cncr.32290. Epub 2019 Aug 9.

PMID:
31398279
7.

Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes?

Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, O'Neil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA.

J Urol. 2019 Dec;202(6):1150-1158. doi: 10.1097/JU.0000000000000392. Epub 2019 Jun 19.

PMID:
31216252
8.

Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.

Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B.

J Manag Care Spec Pharm. 2019 Aug;25(8):889-897. doi: 10.18553/jmcp.2019.19109. Epub 2019 Jun 7.

9.

Re: Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.

Ritch CR, Cookson MS, Clark PE, Chang SS, Fakhoury K, Ralls V, Thu MH, Penson DF, Smith JA Jr, Silver HJ.

J Urol. 2019 Jun 5:101097JU0000000000000375. doi: 10.1097/JU.0000000000000375. [Epub ahead of print] No abstract available.

PMID:
31166841
10.

The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Cooperberg MR, Carroll PR, Dall'Era MA, Davies BJ, Davis JW, Eggener SE, Feng FY, Lin DW, Morgan TM, Morgans AK, Spratt DE, Taneja SS, Penson DF.

Eur Urol. 2019 Sep;76(3):268-272. doi: 10.1016/j.eururo.2019.05.013. Epub 2019 May 23.

PMID:
31128968
11.

Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology.

Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA.

J Natl Compr Canc Netw. 2019 May 1;17(5):479-505. doi: 10.6004/jnccn.2019.0023.

PMID:
31085757
12.

Functional Recovery Following Primary Treatment for Prostate Cancer: Update from the CEASAR Study.

Barocas DA, Penson DF; CEASAR Investigators.

Eur Urol Focus. 2019 May 6. pii: S2405-4569(19)30108-7. doi: 10.1016/j.euf.2019.04.001. [Epub ahead of print]

PMID:
31072805
13.

Modeling economic and epidemiological impact of voluntary medical male circumcision among men who have sex with men in Beijing, China.

Zhang C, Penson DF, Qian HZ, Webb GF, Lou J, Shephard BE, Liu Y, Vermund SH.

Int J STD AIDS. 2019 Jun;30(7):630-638. doi: 10.1177/0956462419831859. Epub 2019 Mar 19.

PMID:
30890118
14.

Predictors of Response Outcomes for Research Recruitment Through a Central Cancer Registry: Evidence From 17 Recruitment Efforts for Population-Based Studies.

Millar MM, Kinney AY, Camp NJ, Cannon-Albright LA, Hashibe M, Penson DF, Kirchhoff AC, Neklason DW, Gilsenan AW, Dieck GS, Stroup AM, Edwards SL, Bateman C, Carter ME, Sweeney C.

Am J Epidemiol. 2019 May 1;188(5):928-939. doi: 10.1093/aje/kwz011.

PMID:
30689685
15.

The association between Medicare accountable care organization enrollment and breast, colorectal, and prostate cancer screening.

Resnick MJ, Graves AJ, Gambrel RJ, Thapa S, Buntin MB, Penson DF.

Cancer. 2018 Nov 15;124(22):4366-4373. doi: 10.1002/cncr.31700. Epub 2018 Nov 9.

PMID:
30412287
16.

Perioperative Oral Nutrition Supplementation Reduces Prevalence of Sarcopenia following Radical Cystectomy: Results of a Prospective Randomized Controlled Trial.

Ritch CR, Cookson MS, Clark PE, Chang SS, Fakhoury K, Ralls V, Thu MH, Penson DF, Smith JA Jr, Silver HJ.

J Urol. 2019 Mar;201(3):470-477. doi: 10.1016/j.juro.2018.10.010.

PMID:
30359680
17.

Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Oct 1;18(1):84. doi: 10.1186/s12894-018-0397-5.

18.

Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.

Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

BMC Urol. 2018 Sep 6;18(1):77. doi: 10.1186/s12894-018-0387-7. Erratum in: BMC Urol. 2018 Oct 1;18(1):84.

19.

Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures.

Lee DJ, Barocas DA, Zhao Z, Huang LC, Koyama T, Resnick MJ, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF, Hoffman KE.

Pract Radiat Oncol. 2018 Sep - Oct;8(5):307-316. doi: 10.1016/j.prro.2018.04.009.

PMID:
30177030
20.

Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.

Lee DJ, Barocas DA, Zhao Z, Huang LC, Resnick MJ, Koyoma T, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF, Hoffman KE.

Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):116-126. doi: 10.1016/j.ijrobp.2018.05.043. Epub 2018 Jun 1.

PMID:
30102188
21.

Racial variation in receipt of quality radiation therapy for prostate cancer.

Lee DJ, Zhao Z, Huang LC, Koyoma T, Resnick MJ, Penson DF, Barocas DA, Hoffman KE.

Cancer Causes Control. 2018 Oct;29(10):895-899. doi: 10.1007/s10552-018-1065-5. Epub 2018 Aug 11.

PMID:
30099628
22.

Fibromyxoid Nephrogenic Adenoma in the Ureter.

Dropkin BM, Giannico GA, Reisz PA, Penson DF, Hsi RS.

J Endourol Case Rep. 2018 Jul 1;4(1):97-99. doi: 10.1089/cren.2018.0037. eCollection 2018.

23.

Multiparametric magnetic resonance imaging (MRI) with targeted fusion biopsy: is the time now?

Laviana AA, Penson DF.

BJU Int. 2018 Jul;122(1):1-2. doi: 10.1111/bju.14244. No abstract available.

24.

Re: Americans Support Price Shopping for Health Care, but Few Actually Seek out Price Information.

Penson DF.

J Urol. 2018 Apr;199(4):884-885. doi: 10.1016/j.juro.2018.01.029. Epub 2018 Jan 17. No abstract available.

PMID:
29642346
25.

Re: Sustained Gains in Coverage, Access, and Affordability under the ACA: A 2017 Update.

Penson DF.

J Urol. 2018 Apr;199(4):883-885. doi: 10.1016/j.juro.2018.01.027. Epub 2018 Jan 17. No abstract available.

PMID:
29642345
26.

Re: Narrow Networks on the Health Insurance Marketplaces: Prevalence, Pricing, and the Cost of Network Breadth.

Penson DF.

J Urol. 2018 Apr;199(4):883-884. doi: 10.1016/j.juro.2018.01.028. Epub 2018 Jan 17. No abstract available.

PMID:
29642344
27.

Medicare Accountable Care Organization Enrollment and Appropriateness of Cancer Screening.

Resnick MJ, Graves AJ, Thapa S, Gambrel R, Tyson MD, Lee D, Buntin MB, Penson DF.

JAMA Intern Med. 2018 May 1;178(5):648-654. doi: 10.1001/jamainternmed.2017.8087.

28.

Re: Projecting the Urology Workforce over the Next 20 Years.

Penson DF.

J Urol. 2017 May;197(5):1339. doi: 10.1016/j.juro.2017.02.054. Epub 2017 Feb 20. No abstract available.

PMID:
29539952
29.

Re: Better Patient Care at High-Quality Hospitals May Save Medicare Money and Bolster Episode-Based Payment Models.

Penson DF.

J Urol. 2017 May;197(5):1338-1339. doi: 10.1016/j.juro.2017.02.053. Epub 2017 Feb 20. No abstract available.

PMID:
29539950
30.

Re: Changes in Health Status and Care Use after ACA Expansions among the Insured and Uninsured.

Penson DF.

J Urol. 2017 May;197(5):1337-1338. doi: 10.1016/j.juro.2017.01.012. Epub 2017 Jan 10. No abstract available.

PMID:
29539949
31.

Re: Uncompensated Care Decreased at Hospitals in Medicaid Expansion States but Not at Hospitals in Nonexpansion States.

Penson DF.

J Urol. 2017 May;197(5):1337-1338. doi: 10.1016/j.juro.2017.01.013. Epub 2017 Jan 10. No abstract available.

PMID:
29539948
32.

Re: Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated with New Cancer Medicines.

Penson DF.

J Urol. 2017 May;197(5):1220-1221. doi: 10.1016/j.juro.2017.02.055. Epub 2017 Feb 20. No abstract available.

PMID:
29539893
33.

Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.

Tyson MD 2nd, Koyama T, Lee D, Hoffman KE, Resnick MJ, Wu XC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Chen V, Conwill R, McCollum D, Penson DF, Barocas DA.

Eur Urol. 2018 Jul;74(1):26-33. doi: 10.1016/j.eururo.2018.02.012. Epub 2018 Feb 28.

PMID:
29501451
34.

Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET.

Flanders SC, Kim J, Wilson S, Braziunas J, Greenfield S, Billimek J, Lechpammer S, Lin DW, Karsh L, Quinn DI, Shevrin D, Shore ND, Symanowski JT, Penson DF.

Future Oncol. 2018 Mar;14(6):527-536. doi: 10.2217/fon-2017-0438. Epub 2018 Feb 8.

35.

Editorial Comment.

Penson DF.

J Urol. 2018 May;199(5):1232. doi: 10.1016/j.juro.2017.10.073. Epub 2018 Feb 3. No abstract available.

PMID:
29406274
36.

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Faiena I, Holden S, Cooperberg MR, Holden S, Soule HR, Simons JW, Morgan TM, Penson DF, Morgans AK, Hussain M.

J Clin Oncol. 2018 Apr 1;36(10):937-941. doi: 10.1200/JCO.2017.76.4050. Epub 2018 Feb 5. No abstract available.

37.

Re: Low-Volume vs High-Volume Centers and Management of Fournier's Gangrene in Washington State.

Penson DF.

J Urol. 2017 Aug;198(2):248. doi: 10.1016/j.juro.2017.05.022. Epub 2017 May 10. No abstract available.

PMID:
29370639
38.

Re: National Health Spending: Faster Growth in 2015 as Coverage Expands and Utilization Increases.

Penson DF.

J Urol. 2017 Aug;198(2):247. doi: 10.1016/j.juro.2017.05.021. Epub 2017 May 11. No abstract available.

PMID:
29370637
39.

Re: At Federally Funded Health Centers, Medicaid Expansion was Associated with Improved Quality of Care.

Penson DF.

J Urol. 2017 Aug;198(2):246-247. doi: 10.1016/j.juro.2017.05.020. Epub 2017 May 11. No abstract available.

PMID:
29370636
40.

Re: Medicare's Acute Care Episode Demonstration: Effects of Bundled Payments on Costs and Quality of Surgical Care.

Penson DF.

J Urol. 2018 Feb;199(2):333-334. doi: 10.1016/j.juro.2017.11.040. Epub 2017 Nov 9. No abstract available.

PMID:
29357548
41.

Re: Strategies for Identifying and Closing the Gender Salary Gap in Surgery.

Penson DF.

J Urol. 2018 Feb;199(2):332-334. doi: 10.1016/j.juro.2017.11.039. Epub 2017 Nov 9. No abstract available.

PMID:
29357547
42.

Considering quantity and quality of life in metastatic castration-naive prostate cancer.

Penson DF.

Lancet Oncol. 2018 Feb;19(2):153-154. doi: 10.1016/S1470-2045(17)30908-7. Epub 2018 Jan 8. No abstract available.

PMID:
29326027
43.

Re: Effect of Electroacupuncture on Urinary Leakage among Women with Stress Urinary Incontinence: A Randomized Clinical Trial.

Penson DF.

J Urol. 2018 Jan;199(1):35-36. doi: 10.1016/j.juro.2017.09.112. Epub 2017 Oct 10. No abstract available.

PMID:
29310198
44.

Re: Electronic Health Record Logs Indicate that Physicians Split Time Evenly between Seeing Patients and Desktop Medicine.

Penson DF.

J Urol. 2018 Jan;199(1):20. doi: 10.1016/j.juro.2017.09.105. Epub 2017 Oct 9. No abstract available.

PMID:
29310172
45.

Re: Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.

Penson DF.

J Urol. 2018 Jan;199(1):19-20. doi: 10.1016/j.juro.2017.09.104. Epub 2017 Oct 9. No abstract available.

PMID:
29310169
46.

Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer.

Sonnenburg D, Chaudhuri P, Graves AJ, Penson DF, Morgans AK.

Clin Oncol Res. 2018;1(3):2-7. doi: 10.31487/j.COR.2018.03.001. Epub 2018 Sep 6.

47.

The Effect of Nerve Sparing Status on Sexual and Urinary Function: 3-Year Results from the CEASAR Study.

Avulova S, Zhao Z, Lee D, Huang LC, Koyama T, Hoffman KE, Conwill RM, Wu XC, Chen V, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Paddock LE, Stroup A, Resnick MJ, Penson DF, Barocas DA.

J Urol. 2018 May;199(5):1202-1209. doi: 10.1016/j.juro.2017.12.037. Epub 2017 Dec 16. Erratum in: J Urol. 2018 Aug;200(2):458.

PMID:
29253578
48.

Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.

Giri VN, Knudsen KE, Kelly WK, Abida W, Andriole GL, Bangma CH, Bekelman JE, Benson MC, Blanco A, Burnett A, Catalona WJ, Cooney KA, Cooperberg M, Crawford DE, Den RB, Dicker AP, Eggener S, Fleshner N, Freedman ML, Hamdy FC, Hoffman-Censits J, Hurwitz MD, Hyatt C, Isaacs WB, Kane CJ, Kantoff P, Karnes RJ, Karsh LI, Klein EA, Lin DW, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann MJ, Mark JR, McCue PA, Miner MM, Morgan T, Moul JW, Myers RE, Nielsen SM, Obeid E, Pavlovich CP, Peiper SC, Penson DF, Petrylak D, Pettaway CA, Pilarski R, Pinto PA, Poage W, Raj GV, Rebbeck TR, Robson ME, Rosenberg MT, Sandler H, Sartor O, Schaeffer E, Schwartz GF, Shahin MS, Shore ND, Shuch B, Soule HR, Tomlins SA, Trabulsi EJ, Uzzo R, Vander Griend DJ, Walsh PC, Weil CJ, Wender R, Gomella LG.

J Clin Oncol. 2018 Feb 1;36(4):414-424. doi: 10.1200/JCO.2017.74.1173. Epub 2017 Dec 13. Review.

49.

The influence of provider characteristics and market forces on response to financial incentives.

O'Neil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ.

Am J Manag Care. 2017 Nov;23(11):662-667.

50.

Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts.

Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R.

Ann Intern Med. 2018 Jan 2;168(1):1-9. doi: 10.7326/M17-0548. Epub 2017 Nov 28.

Supplemental Content

Loading ...
Support Center